

Leslie Chong Appointed Chief Executive Officer of Imugene Ltd (ASX:IMU)

- IMU strengthens leadership promoting Ms. Leslie Chong from Chief Operating Officer to Chief Executive Officer
- Appointment comes as the Company prepares for the critical milestone of dosing the patients in the gastric cancer Phase 1b/2 clinical trial in Asia

Melbourne, Australia, 21 November 2016: Imugene today announced that it will promote Chief Operating Officer, Ms. Leslie Chong to the position of Chief Executive Officer (CEO).

Ms. Chong joined IMU in September 2015 from the pharmaceutical giant, Genentech, in San Francisco where she had a distinguished career across many aspects of drug development.

Executive Chairman Mr. Paul Hopper said: "We are delighted to announce Leslie's enhanced role in the Company. Over the past year she has demonstrated a clear understanding of the nuances of the Australian market for life sciences, has developed a strong rapport with our investors and led the recent successful capital raising with great aplomb. We look forward to the future under her leadership."

Ms. Leslie Chong said "I am honored that Imugene's distinguished board of directors have appointed me to this position. This confidence in me strengthens my resolve and conviction to continue the work of growing Imugene into a formidable biotech company."

Imugene has undertaken re-nominating Ms. Chong's visa application for this changed appointment which will take effect upon issue of this re-nominated visa.

Remuneration Changes

Further to the appointment of Ms. Chong as CEO, the remuneration for Ms. Chong has been changed as shown below in line with position demands and responsibilities of the role. Additionally, Mr. Hopper, has elected to reduce his remuneration by 50%, and accrual of the deferred unpaid component (as shown in the Annual Report) will cease.

Appointment	Position	From	To	
Ms Leslie Chong	Chief Executive Officer	AU\$275,000	AU\$300,000 Plus up to 30% bonus subject to performance milestones	All other terms and conditions remain the same
Mr Paul Hopper	Executive Chairman	US\$200,000	AU\$137,400	All other terms and conditions remain the same

About Imugene

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

For further information, please visit www.imugene.com.

Sign up to follow @TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>.

To follow Imugene on Facebook visit www.facebook.com/imugene.

Paul Hopper
Executive Chairman

Tel: +61 406 671 515 (Australia)
receptogen@earthlink.net